(-0.01%) 5 477.75 points
(-0.02%) 38 810 points
(0.01%) 19 924 points
(0.26%) $80.54
(1.11%) $2.82
(0.11%) $2 331.60
(-0.43%) $29.27
(-0.11%) $969.80
(0.03%) $0.932
(-0.13%) $10.64
(0.08%) $0.788
(-1.86%) $86.81
Live Chart Being Loaded With Signals
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs...
Stats | |
---|---|
Šios dienos apimtis | 1.11M |
Vidutinė apimtis | 2.57M |
Rinkos kapitalizacija | 369.56M |
EPS | $-0.0718 ( Q1 | 2024-05-09 ) |
Kita pelno data | ( $0.0200 ) 2024-07-25 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-70.56 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0130 (0.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-22 | Chrousos Phaedra | Buy | 21 887 | Common Stock |
2024-05-22 | Chrousos Phaedra | Buy | 40 202 | Stock Option (right to buy) |
2024-05-17 | Honore Tage | Buy | 20 529 | Common Stock |
2024-05-17 | Honore Tage | Buy | 37 578 | Stock Option (right to buy) |
2024-05-17 | Dugan Richard W | Buy | 20 529 | Common Stock |
INSIDER POWER |
---|
72.84 |
Last 99 transactions |
Buy: 2 812 252 | Sell: 593 917 |
Tūris Koreliacija
Vanda Pharmaceuticals Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
NEXT | 0.804 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Vanda Pharmaceuticals Inc Koreliacija - Valiuta/Žaliavos
Vanda Pharmaceuticals Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $192.64M |
Bruto pelnas: | $175.75M (91.23 %) |
EPS: | $0.0437 |
FY | 2023 |
Pajamos: | $192.64M |
Bruto pelnas: | $175.75M (91.23 %) |
EPS: | $0.0437 |
FY | 2022 |
Pajamos: | $254.38M |
Bruto pelnas: | $230.10M (90.45 %) |
EPS: | $0.110 |
FY | 2021 |
Pajamos: | $268.68M |
Bruto pelnas: | $243.05M (90.46 %) |
EPS: | $0.610 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.